MedTrace Logo

Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia

NCT04008381 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-08-07

No results posted yet for this study

Summary

This study investigates the potential curative properties of ex-vivo expanded gamma delta T-cells obtained from a blood-related donor for patients with relapsed or refractory acute myeloid leukemia.

Conditions

Interventions

BIOLOGICAL

Ex-vivo Expanded γδ T Lymphocytes

Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).

Sponsors & Collaborators

  • Jinan University, China

    collaborator UNKNOWN

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Heng Mei, M.D. Ph.D · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-07-01
Completion
2023-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008381 on ClinicalTrials.gov